← Back to screener

Eton Pharmaceuticals, Inc. ETON

Rank #2388 · Nasdaq · $1.4B market cap
Audited by GRANT THORNTON LLP, no going-concern flag in the latest filing.
Score
21.1
P/E
-1527.1
P/B
109.29
ROE
-7.2%
Op. Margin
-3.8%
Debt Ratio
395%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -1527.1x, P/B 109.29x. Ranks in the top 79% of the universe.

Profitability ★☆☆☆☆
Weak

ROE -7.2%. Ranks in the top 74% of the universe.

Safety ★☆☆☆☆
Weak

Debt ratio 395%. Ranks in the top 76% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★★
Excellent

Revenue growth of 48.9% year over year. Ranks in the top 8% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2018–$-0.0B$-0.0B$-0.0B–-19
2019$0.0B$-0.0B$-0.0B$-0.0B-1076.2-29
2020$0.0B$-0.0B$-0.0B$-0.0B-1076.2-95
2021$0.0B$-0.0B$-0.0B$0.0B-1939.641
2022$0.0B$-0.0B$-0.0B$0.0B-69515.493
2023$0.0B$-0.0B$-0.0B$0.0B-6.876
2024$0.0B$-0.0B$-0.0B$0.0B-38.992
2025$0.0B$-0.0B$-0.0B$0.0B-3.8395

← See the full screener